PURE Quote, Financials, Valuation and Earnings

The Estée Lauder Companies, Inc. has a net margin of -65.54% compared to PURE Bioscience, Inc.'s net margin of 1.35%. PURE Bioscience, Inc.'s return on equity of -- beat The Estée Lauder Companies, Inc.'s return on equity of -21.78%.

PURE Bioscience, Inc. has a consensus price target of --, signalling upside risk potential of 6144.8%. On the other hand The Estée Lauder Companies, Inc. has an analysts' consensus of $104.30 which suggests that it could fall by -2.25%. Given that PURE Bioscience, Inc. has higher upside potential than The Estée Lauder Companies, Inc., analysts believe PURE Bioscience, Inc. is more attractive than The Estée Lauder Companies, Inc..

PURE Bioscience, Inc. has a beta of 0.513, which suggesting that the stock is 48.679% less volatile than S&P 500. In comparison The Estée Lauder Companies, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.189%.

PURE Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Estée Lauder Companies, Inc. offers a yield of 1.31% to investors and pays a quarterly dividend of $0.35 per share. PURE Bioscience, Inc. pays -- of its earnings as a dividend. The Estée Lauder Companies, Inc. pays out 54.55% of its earnings as a dividend. The Estée Lauder Companies, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PURE Bioscience, Inc. quarterly revenues are $708K, which are smaller than The Estée Lauder Companies, Inc. quarterly revenues of $3.5B. PURE Bioscience, Inc.'s net income of -$464K is lower than The Estée Lauder Companies, Inc.'s net income of $47M. Notably, PURE Bioscience, Inc.'s price-to-earnings ratio is -- while The Estée Lauder Companies, Inc.'s PE ratio is 124.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PURE Bioscience, Inc. is 2.28x versus 2.67x for The Estée Lauder Companies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Edgewell Personal Care Co. has a net margin of -65.54% compared to PURE Bioscience, Inc.'s net margin of -5.7%. PURE Bioscience, Inc.'s return on equity of -- beat Edgewell Personal Care Co.'s return on equity of 1.65%.

PURE Bioscience, Inc. has a consensus price target of --, signalling upside risk potential of 6144.8%. On the other hand Edgewell Personal Care Co. has an analysts' consensus of $23.86 which suggests that it could grow by 37.27%. Given that PURE Bioscience, Inc. has higher upside potential than Edgewell Personal Care Co., analysts believe PURE Bioscience, Inc. is more attractive than Edgewell Personal Care Co..

PURE Bioscience, Inc. has a beta of 0.513, which suggesting that the stock is 48.679% less volatile than S&P 500. In comparison Edgewell Personal Care Co. has a beta of 0.610, suggesting its less volatile than the S&P 500 by 39.018%.

PURE Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewell Personal Care Co. offers a yield of 3.45% to investors and pays a quarterly dividend of $0.15 per share. PURE Bioscience, Inc. pays -- of its earnings as a dividend. Edgewell Personal Care Co. pays out 112.44% of its earnings as a dividend.

PURE Bioscience, Inc. quarterly revenues are $708K, which are smaller than Edgewell Personal Care Co. quarterly revenues of $537.2M. PURE Bioscience, Inc.'s net income of -$464K is higher than Edgewell Personal Care Co.'s net income of -$30.6M. Notably, PURE Bioscience, Inc.'s price-to-earnings ratio is -- while Edgewell Personal Care Co.'s PE ratio is 33.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PURE Bioscience, Inc. is 2.28x versus 0.37x for Edgewell Personal Care Co.. Usually stocks with elevated PS ratios are considered overvalued.

Interparfums, Inc. has a net margin of -65.54% compared to PURE Bioscience, Inc.'s net margin of 19.39%. PURE Bioscience, Inc.'s return on equity of -- beat Interparfums, Inc.'s return on equity of 20.27%.

PURE Bioscience, Inc. has a consensus price target of --, signalling upside risk potential of 6144.8%. On the other hand Interparfums, Inc. has an analysts' consensus of $103.60 which suggests that it could grow by 22.36%. Given that PURE Bioscience, Inc. has higher upside potential than Interparfums, Inc., analysts believe PURE Bioscience, Inc. is more attractive than Interparfums, Inc..

PURE Bioscience, Inc. has a beta of 0.513, which suggesting that the stock is 48.679% less volatile than S&P 500. In comparison Interparfums, Inc. has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.118%.

PURE Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Interparfums, Inc. offers a yield of 3.78% to investors and pays a quarterly dividend of $0.80 per share. PURE Bioscience, Inc. pays -- of its earnings as a dividend. Interparfums, Inc. pays out 58.64% of its earnings as a dividend. Interparfums, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PURE Bioscience, Inc. quarterly revenues are $708K, which are smaller than Interparfums, Inc. quarterly revenues of $429.6M. PURE Bioscience, Inc.'s net income of -$464K is lower than Interparfums, Inc.'s net income of $83.3M. Notably, PURE Bioscience, Inc.'s price-to-earnings ratio is -- while Interparfums, Inc.'s PE ratio is 16.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PURE Bioscience, Inc. is 2.28x versus 1.86x for Interparfums, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United-Guardian, Inc. has a net margin of -65.54% compared to PURE Bioscience, Inc.'s net margin of 11.85%. PURE Bioscience, Inc.'s return on equity of -- beat United-Guardian, Inc.'s return on equity of 17.45%.

PURE Bioscience, Inc. has a consensus price target of --, signalling upside risk potential of 6144.8%. On the other hand United-Guardian, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PURE Bioscience, Inc. has higher upside potential than United-Guardian, Inc., analysts believe PURE Bioscience, Inc. is more attractive than United-Guardian, Inc..

PURE Bioscience, Inc. has a beta of 0.513, which suggesting that the stock is 48.679% less volatile than S&P 500. In comparison United-Guardian, Inc. has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.302%.

PURE Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United-Guardian, Inc. offers a yield of 9.84% to investors and pays a quarterly dividend of $0.25 per share. PURE Bioscience, Inc. pays -- of its earnings as a dividend. United-Guardian, Inc. pays out 84.79% of its earnings as a dividend. United-Guardian, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PURE Bioscience, Inc. quarterly revenues are $708K, which are smaller than United-Guardian, Inc. quarterly revenues of $2.3M. PURE Bioscience, Inc.'s net income of -$464K is lower than United-Guardian, Inc.'s net income of $268.4K. Notably, PURE Bioscience, Inc.'s price-to-earnings ratio is -- while United-Guardian, Inc.'s PE ratio is 14.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PURE Bioscience, Inc. is 2.28x versus 2.79x for United-Guardian, Inc.. Usually stocks with elevated PS ratios are considered overvalued.